Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 2015. The report serves as a notification to the market regarding the Company's total voting rights and capital structure as of October 31, 2015, in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital and voting rights data.
- Issued Share Capital (as of Oct 31, 2015): 5,358,384,189 Ordinary Shares of 25p each.
- Treasury Shares: 491,515,950 Ordinary Shares.
- Total Voting Rights: 4,866,868,239.
Material Changes
The filing text does not provide a clear value for material changes versus the prior comparable period. The document is a static notification of capital structure rather than a comparative financial performance report.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document contains no forward-looking statements or risk disclosures beyond the regulatory requirement to notify shareholders of the voting rights denominator for disclosure calculations.
Important Facts for Investors
- Investors should verify the total number of voting rights (4,866,868,239) as the denominator for calculating notification thresholds under the Financial Conduct Authority's Disclosure and Transparency Rules.
- Confirm the number of shares held in Treasury (491,515,950) when assessing the Company's issued share capital.
- Note that this filing does not contain financial performance data; investors must refer to other reports for revenue and profit metrics.